Lifecore Proxy Sets Vote on $6.28 Cash Takeover; Go-Shop Ends With No Rival Bid
LFCR sits 77% above its 52-week low of $3.625 on elevated volume (2.7× avg).
Summary
Lifecore's preliminary proxy asks stockholders to approve the $6.28-per-share cash merger with Webster Equity Partners plus CVRs worth up to $160 million; the go-shop ended October 28, 2026 with no competing bid.
Key Events · M&A and Partnerships · LFCR
-
Merger Terms: $6.28 Cash Plus CVR
Each common share converts into $6.28 in cash plus one CVR; Series A Preferred receives its Conversion Amount ($6.53 per as-converted common share as of September 27, 2026) plus one CVR per conversion share.
-
CVR Pays Up to $160 Million
Milestones: $30 million on 2028 non-Alcon revenue of $120 million (scaled from $100 million), $45 million on 2029 non-Alcon revenue of $175 million (scaled from $145 million), and $85 million on 2030 consolidated EBITDA of $120 million.
-
Go-Shop Ends With No Rival Bid
The 30-day go-shop expired at 11:59 p.m. Eastern on October 28, 2026 with no acquisition proposal; Bourne contacted 110 counterparties, three signed NDAs, 84 declined and 26 did not respond.
-
Vote Mechanics and Locked-Up Holders
Record date is November 4, 2026; approval needs a majority of 45,731,728 combined votes (37,905,846 common plus 7,825,882 as-converted preferred), and Wynnefield and Legion support agreements cover about 27.34%.
Analysis · LFCR · Life Sciences
This is the definitive solicitation document for the Webster Equity Partners buyout: common holders get $6.28 per share in cash plus one CVR per share, with up to $160 million in milestone payments if 2028, 2029 and 2030 targets are hit. The key new fact is that the 30-day go-shop, which ran through October 28, 2026, produced no acquisition proposal after Bourne contacted 110 counterparties — so the $6.28 price is effectively the final one and the vote is the last hurdle. The $6.28 cash is a 49.5% premium to the $4.20 close on September 25, 2026, the last trading day before signing, and the stock at $6.40 today already trades above the cash price, meaning the market is pricing in closing plus some CVR value. Approval needs a majority of the combined common and as-converted preferred voting power, and holders tied to Wynnefield and Legion (about 27.34%) are locked in. The downside case is explicit: if the deal breaks, the company stays public with a $52.1 million preferred redemption due December 28, 2026 that it cannot fund without lender consent.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFCR was trading at $6.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $242.6M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.